This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
ILD medications: nintedanib
ILD_NINTENDANIB
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
194 |
4. Check minimum number of events
Min. number of events
3
|
194 |
5. Include endpointsNone |
194 |
6. Filter based on genotype QC (FinnGen only) |
194 |
Control definitions (FinnGen only)
- Control exclude
- ILD_MEDICATIONS
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
ILD medications: nintedanib
based on the number of shared cases.
Similar with more cases:
- L01XE Protein kinase inhibitors
- Idiopathic pulmonary fibrosis
- ILD, hospital admissions 1, main diag only
- ILD, hospital admissions
- Other interstitial pulmonary diseases
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 194 | 58 | 136 |
| Unadjusted period prevalence (%) | 0.05 | 0.02 | 0.06 |
| Median age at first event (years) | 70.52 | 71.20 | 70.22 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 183
- Matched controls
- 1831
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
284
Kela drug reimbursment
Nintedanib and pirfenidone
+∞
264.8
183
*
L01XE31
ATC
[U] nintedanib; oral
+∞
264.8
183
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
+∞
251.2
183
8
356
Kela drug reimbursment
Nintedanib and pirfenidone
+∞
182.0
143
*
L01EX09
ATC
nintedanib; oral
+∞
116.5
99
*
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
186.5
95.2
93
10
L04AX05
ATC
pirfenidone; oral
+∞
86.5
76
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
58.8
83.6
98
35
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
54.1
62.0
73
22
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
57.8
57.7
67
18
XG410
NOMESCO Finland
Flow-volume spirometry
35.9
47.3
61
25
H02AB06
ATC
prednisolone; systemic
9.2
41.7
129
376
UGC12
NOMESCO Finland
Flexible bronchoscopy
14.2
41.4
77
89
GD1AA
NOMESCO Finland
Thorax X-ray examination
9.6
37.9
153
633
TGC00
NOMESCO Finland
Bronchial lavation
27.2
31.9
44
21
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
14.2
29.8
53
51
R03AC02
ATC
salbutamol; inhalant
6.1
28.2
134
564
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
24.6
25.6
36
18
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
7.5
25.1
67
131
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
18.9
24.6
38
25
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
137.2
23.2
24
*
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
124.3
21.1
22
*
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
82.6
20.2
22
*
GD1AD
NOMESCO Finland
Thorax CT examination
12.2
19.5
36
36
J96.1
ICD-10 Finland
Chronic respiratory failure
28.7
18.8
25
10
R06.0
ICD-10 Finland
Dyspnoea
4.2
16.9
80
283
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
33.6
16.5
21
7
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.2
15.8
75
262
WX721
NOMESCO Finland
Oxygen concentrator therapy
162.4
14.7
15
*
R03BA08
ATC
ciclesonide; inhalant
8.2
14.5
33
48
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
6.6
14.2
38
70
R05
ICD-10 Finland
Cough
4.1
13.9
63
207
L04AA06
ATC
mycophenolic acid; systemic
+∞
13.7
13
*
Z51.5
ICD-10 Finland
Palliative care
5.9
13.0
38
78
Z94.2
ICD-10 Finland
Lung transplant status
+∞
12.6
12
*
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
12.6
12
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.3
12.1
81
358
R28
ICPC
Limited function/disability (R)
32.4
11.8
15
5
127
Kela drug reimbursment
Transplant complication
+∞
10.5
10
*
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
34.8
10.5
13
*
J47
ICD-10 Finland
Bronchiectasis
21.5
10.0
14
7
N02AA01
ATC
morphine; systemic, rectal
21.5
10.0
14
7
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.0
9.7
72
329
R01AD12
ATC
fluticasone furoate; nasal
3.2
9.5
56
219
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
9.4
71
329
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
5.9
9.4
26
50
R03AK08
ATC
formoterol and beclometasone; inhalant
10.9
9.2
17
17
XG466
NOMESCO Finland
Sleep oxymetry
8.2
9.2
20
27
R03BB04
ATC
tiotropium bromide; inhalant
4.3
9.1
35
96
L04AX01
ATC
azathioprine; systemic
38.8
9.1
11
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
12.4
8.7
15
13
R02
ICPC
Shortness of breath/dyspnoea
3.9
8.5
36
108
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
94.2
8.5
9
*
R05
ICPC
Cough
3.1
8.4
53
215
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
+∞
8.4
8
*
J01FA06
ATC
roxithromycin; oral
2.6
8.4
82
433
J01FA10
ATC
azithromycin; systemic
2.5
8.2
103
625
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.8
7.9
26
61
A02BC02
ATC
pantoprazole; systemic
2.4
7.2
131
930
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.3
7.0
36
126
J01CA04
ATC
amoxicillin; systemic
2.6
7.0
146
1103
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.6
7.0
17
28
R03BA01
ATC
beclometasone; inhalant
3.5
6.9
32
104
XJC10
NOMESCO Finland
Oesophageal pH monitoring
23.5
6.7
9
*
R4110
NOMESCO Finland
Physiotherapy
2.4
6.6
66
345
R03AK07
ATC
formoterol and budesonide; inhalant
3.1
6.5
37
139
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
5.2
6.4
19
40
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.2
6.4
93
578
XX4BW
NOMESCO Finland
NA
+∞
6.3
6
*
GX2C5
NOMESCO Finland
Short-lasting oximetry
+∞
6.3
6
*
L04AD01
ATC
ciclosporin; systemic
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
58
30
27.15
77.68
3.1
1.2
—
—
—
0
0
56
29
26.74
74.84
3.1
1.2
—
—
—
0
0
44
14
40.35
69.40
2.8
1.2
—
—
—
0
0
68
63
16.08
67.38
4.6
2.6
—
—
—
0
0
41
15
34.39
61.73
5.3
1.7
57.2
59.1
%
0.23
41
15
41
15
34.39
61.73
5.0
1.6
4.9
4.3
e9/l
0.38
41
15
100
185
10.09
58.94
1.5
1.2
37.9
25.0
iu/ml
0.41
35
48
47
30
20.36
56.54
3.0
1.3
—
—
—
0
0
39
16
30.26
56.33
1.2
1.1
—
—
—
0
0
37
18
25.16
49.93
1.3
1.0
108.0
—
titre
—
5
0
37
18
25.16
49.93
1.2
1.1
1.4
1.6
u/ml
—
11
5
100
227
8.03
47.46
11.0
7.5
1.9
1.0
mmol/l
1.77
88
176
39
24
20.09
47.42
2.9
1.3
—
—
—
0
0
32
13
29.28
46.07
2.7
1.2
—
—
—
0
0
35
19
22.26
44.96
1.1
1.0
2.8
2.5
u/ml
—
25
8
102
251
7.46
44.21
3.4
1.7
—
—
—
0
0
45
44
13.01
42.08
3.1
1.4
—
—
—
0
0
38
28
16.63
42.00
1.9
1.3
—
—
—
0
0
35
23
18.35
41.01
1.9
1.2
—
—
—
0
0
77
175
6.64
35.15
3.5
1.8
—
—
—
0
0
57
99
7.74
33.73
13.3
10.9
25.2
24.4
mmol/l
1.00
52
93
76
177
6.42
33.66
3.5
1.8
—
—
—
0
0
37
6
75.59
33.40
3.4
1.2
—
—
—
0
0
28
18
18.01
32.93
1.1
1.0
357.7
233.3
u/ml
—
23
9
28
19
17.05
32.02
3.5
3.3
—
—
—
0
0
28
19
17.05
32.02
1.1
1.0
—
—
—
0
0
43
58
9.24
31.49
1.3
1.1
167.9
120.3
u/ml
0.49
38
52
34
7
58.44
29.51
3.3
1.4
—
—
—
0
0
34
39
10.36
28.04
2.5
2.2
140.7
126.7
g/l
—
10
30
134
578
5.26
27.34
4.0
2.9
961.0
1401.0
ng/l
1.07
120
499
63
148
5.82
27.07
14.5
6.1
8.2
10.5
mmol/l
2.02
63
143
27
24
12.91
26.36
1.1
1.2
—
—
—
0
0
22
14
17.60
25.79
2.7
1.4
—
—
—
0
0
22
14
17.60
25.79
2.7
1.4
—
—
—
0
0
48
95
6.39
24.56
4.6
3.6
2.2
2.1
mmol/l
0.10
41
75
64
166
5.26
24.34
1.2
1.2
6.6
2.5
u/ml
0.53
15
58
152
793
5.23
22.57
10.8
5.4
1.2
1.2
mmol/l
2.33
146
704
48
103
5.86
22.46
4.9
3.5
5.3
5.1
kpa
0.81
48
96
25
26
10.89
21.92
1.4
1.3
—
—
—
0
0
25
7
40.67
20.39
1.2
1.0
—
—
—
0
0
21
19
12.27
20.11
1.2
1.1
—
—
—
0
0
80
297
3.88
18.37
2.5
1.5
1.5
1.2
mg/l
0.52
70
234
49
128
4.78
18.05
1.5
1.9
1.6
1.7
%
0.60
42
98
26
39
7.54
17.04
3.2
2.1
16.7
16.1
%
—
9
20
20
5
44.23
16.68
4.0
3.4
—
—
—
0
0
43
108
4.83
16.53
18.9
10.4
—
—
—
0
0
194
1585
+∞
16.01
33.8
13.5
22.4
26.8
mg/l
1.43
188
1233
19
5
41.80
15.70
2.0
1.0
—
—
—
0
0
18
20
9.82
14.90
2.4
1.4
87.9
89.6
%
0.35
18
20
144
853
3.67
14.83
12.0
6.1
1.2
1.2
mmol/l
0.45
120
713
15
14
11.53
13.92
1.3
1.4
—
—
—
0
0
15
14
11.53
13.92
1.3
1.4
—
—
—
0
0
15
14
11.53
13.92
1.3
1.4
—
—
—
0
0
37
102
4.25
12.48
1.8
1.6
—
—
—
0
0
17
9
20.53
11.82
1.8
1.0
—
—
—
0
0
97
514
2.77
11.05
4.1
3.0
0.4
0.5
e6/l
0.15
80
376
14
6
24.98
10.40
1.1
1.0
—
—
—
0
0
65
296
2.80
9.70
3.1
1.8
28.3
29.5
s
1.74
65
288
95
523
2.60
9.70
4.0
1.9
108.1
336.1
u/l
1.00
90
491
110
662
2.53
9.14
4.4
3.1
—
—
—
0
0
13
7
19.78
9.06
1.0
1.0
—
—
—
0
0
48
192
2.99
9.03
4.6
2.4
10.3
12.9
umol/l
0.38
48
174
113
711
2.41
8.21
4.1
3.8
41.1
45.4
ng/l
0.09
95
550
11
14
8.27
8.07
1.3
1.2
—
—
—
0
0
32
109
3.32
7.83
1.8
1.6
—
—
—
0
0
62
306
2.51
7.64
3.9
3.1
0.5
0.9
e6/l
0.71
37
177
70
367
2.42
7.56
4.9
3.6
1292.7
419.4
ng/l
1.02
60
315
11
7
16.55
7.32
1.0
1.0
—
—
—
0
0
16
34
5.04
7.31
2.5
1.2
—
—
—
0
0
10
5
20.96
7.21
1.3
1.0
—
—
—
0
0
62
315
2.42
7.12
3.6
2.8
0.4
0.8
e6/l
1.08
39
182
43
186
2.69
6.88
5.6
3.1
—
—
—
0
0
11
9
12.86
6.67
2.6
1.4
—
—
—
0
0
21
60
3.80
6.65
2.5
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
51
4.02
6.54
6.5
2.3
0.3
0.4
u/ml
0.81
11
26
93
579
2.16
6.45
2.7
2.1
71.5
76.3
nmol/l
0.99
83
484
73
413
2.23
6.43
8.0
2.6
8555.3
13385.0
umol/l
0.23
66
341
107
707
2.14
6.33
2.8
2.1
—
—
—
0
0
12
24
5.26
5.82
1.3
1.1
—
—
—
0
0
12
25
5.05
5.57
1.7
2.0
—
—
—
0
0
163
1309
2.53
5.52
38.2
18.2
14.2
13.7
%
4.02
163
1276
11
23
5.01
5.08
1.8
1.5
—
—
—
0
0
11
23
5.01
5.08
1.4
1.5
—
—
—
0
0
50
265
2.19
5.02
2.1
2.4
12.6
13.3
umol/l
0.28
50
238
109
769
1.95
4.94
4.4
3.4
0.0
0.0
estimate
0.00
37
140
109
781
1.90
4.60
4.5
3.4
0.0
0.0
estimate
0.00
36
126
85
562
1.91
4.59
5.6
3.5
2.3
2.3
mmol/l
0.52
78
484
108
774
1.89
4.53
6.2
4.6
0.0
0.0
estimate
0.00
38
138
16
50
3.40
4.44
4.9
2.6
26.1
25.4
mmol/l
0.26
16
43
44
233
2.15
4.39
2.1
2.4
23.9
23.8
%
0.00
36
197
69
439
1.89
4.10
4.2
3.6
0.0
0.0
estimate
0.00
35
129
8
10
8.28
4.10
1.0
1.6
—
—
—
0
0
17
59
3.06
4.01
2.2
1.4
—
—
—
0
0
60
370
1.90
3.89
2.0
1.8
469.6
19192368.1
pmol/l
0.50
48
297
23
98
2.53
3.74
1.3
1.5
—
—
—
0
0
8
12
6.90
3.71
1.0
1.5
—
—
—
0
0
8
12
6.90
3.71
1.0
1.5
—
—
—
0
0
8
12
6.90
3.71
1.0
1.5
—
—
—
0
0
8
13
6.36
3.54
1.0
1.5
—
—
—
0
0
8
13
6.36
3.54
1.0
1.5
—
—
—
0
0
11
34
3.37
3.11
1.9
1.6
—
—
—
0
0
12
41
3.05
2.91
1.9
1.6
—
—
—
0
0
5
6
8.51
2.76
1.6
2.2
—
—
—
0
0
174
1556
2.15
2.74
30.3
14.2
77.2
74.6
ml/min/173m2
1.18
151
1268
160
1392
1.85
2.73
37.0
16.3
39.5
39.6
%
0.03
103
868
7
15
4.80
2.62
1.1
1.1
—
—
—
0
0
9
27
3.44
2.42
1.0
1.1
—
—
—
0
0
12
49
2.54
2.15
1.6
1.2
—
—
—
0
0
10
37
2.80
2.14
1.3
1.2
—
—
—
0
0
10
37
2.80
2.14
1.3
1.2
—
—
—
0
0
6
15
4.09
2.05
1.2
1.3
—
—
—
0
0
11
44
2.59
2.05
1.4
1.3
—
—
—
0
0
180
1664
2.13
2.04
5.4
5.8
2.6
2.6
mmol/l
0.08
159
1494
79
609
1.50
1.99
4.3
3.6
—
—
—
0
0
79
611
1.49
1.95
2.4
2.4
234.2
173.3
ug/l
0.99
74
551
6
16
3.83
1.95
2.2
1.3
—
—
—
0
0
162
1461
1.66
1.86
4.6
4.3
2.0
2.1
mu/l
0.57
143
1266
6
17
3.61
1.85
1.5
2.8
—
—
—
0
0
177
1638
1.92
1.82
5.3
5.2
6.0
6.2
mmol/l
1.32
154
1455
133
1156
1.48
1.74
3.8
3.5
15.0
15.0
pmol/l
0.12
121
988
6
19
3.22
1.67
1.5
1.0
—
—
—
0
0
6
19
3.22
1.67
1.5
1.0
—
—
—
0
0
95
784
1.41
1.59
5.8
3.9
—
—
—
0
0
173
1608
1.70
1.50
4.8
5.1
1.4
1.4
mmol/l
0.18
150
1434
174
1621
1.71
1.47
4.8
5.1
4.4
4.4
mmol/l
0.16
151
1474
60
463
1.43
1.44
1.8
1.4
19.8
21.4
nmol/l
0.35
55
382
26
168
1.63
1.40
3.8
3.3
5.9
5.6
kpa
0.68
26
163
26
168
1.63
1.40
3.8
3.3
1.6
1.5
mmol/l
0.02
21
131
168
1560
1.57
1.34
4.3
4.5
1.3
1.3
mmol/l
0.26
147
1382
25
165
1.59
1.25
3.0
2.0
12.2
13.2
nmol/l
0.30
25
144
7
31
2.30
1.11
1.1
1.1
—
—
—
0
0
168
1584
1.45
0.97
6.4
6.8
41.3
41.1
mmol/mol
0.09
150
1452
38
290
1.39
0.96
1.2
1.2
1.3
1.6
u/ml
—
8
74
18
119
1.57
0.92
2.1
2.3
331.8
390.4
nmol/l
0.73
18
113
6
32
1.90
0.82
1.5
1.3
—
—
—
0
0
45
363
1.31
0.81
2.2
1.7
988.8
1152.9
nmol/l
0.72
35
272
5
26
1.95
0.71
1.4
1.2
—
—
—
0
0
20
148
1.39
0.62
1.3
1.3
—
—
—
0
0
6
36
1.69
0.57
1.7
1.1
—
—
—
0
0
29
233
1.29
0.55
4.0
5.1
33.4
31.0
%
0.58
20
137
9
62
1.47
0.54
1.0
1.0
—
—
—
0
0
26
207
1.30
0.53
2.9
3.5
299.2
245.6
u/l
1.28
26
197
109
1010
1.18
0.51
3.8
5.5
1.6
2.7
ug/l
2.42
95
895
14
101
1.42
0.51
2.2
2.3
1.4
1.2
%
0.39
14
101
47
404
1.22
0.51
2.8
2.2
—
—
—
0
0
52
585
0.85
0.43
2.4
3.2
0.6
0.8
ug/l
1.90
38
418
0
16
0.00
0.41
0.0
1.1
—
40.0
—
0
9
0
16
0.00
0.41
0.0
1.0
—
436.7
—
0
10
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
6
42
1.44
0.36
2.7
1.4
58.4
2.8
mg/l
—
6
31
13
101
1.31
0.32
3.3
3.3
0.1
0.2
e6/l
0.53
13
101
5
71
0.70
0.26
1.0
1.6
—
—
—
0
0
80
755
1.10
0.24
2.2
2.0
95.2
91.3
pmol/l
0.20
44
368
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
12
103
1.18
0.14
1.5
1.3
—
—
—
0
0
21
199
1.06
0.05
1.6
5.5
14.1
42.9
ug/l
0.56
16
169
81
821
0.98
0.03
3.1
4.7
21.6
21.5
%
0.02
30
421
24
234
1.03
0.00
6.5
7.2
—
—
—
0
0
49
493
0.99
0.00
1.8
1.7
1.7
1.3
mmol/l
1.28
38
394
14
145
0.96
0.00
2.1
2.7
4.7
4.5
kpa
0.19
14
139
0
5
0.00
0.00
0.0
1.0
—
1447.8
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
0.3
—
0
5
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
225.0
—
0
8
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
3.7
—
68.8
—
0
6
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
46.6
—
0
7
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.6
—
68.9
—
0
8
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ILD_NINTENDANIB – ILD medications: nintedanib
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).